Richard Wilson has spent the last 25 years in the pharmaceutical industry in a broad range of roles ranging from research project ideation to commercialization strategy. He is presently Director of Corporate Partnerships at Innoviva, a 14-person pharmaceutical royalty investment company, where he is splits his time between commercial strategy and data analytics support for partnered respiratory medicines, competitive intelligence and new business development.
Prior to this role, Richard spent his career in research and development, in both large (Glaxo Group Research, UK) and smaller pharmaceutical companies (Biochem Pharma, Montreal, and Theravance/Advanced Medicine, South San Francisco) where he has led teams as a medicinal chemist, a project lead, a CMC lead, and an alliance, project and portfolio management professional. Richard has led project work within a range of academic and industrial collaborations including partnerships with AstraZeneca, GSK and Merck and with contract research organizations in Europe and in Asia. During his time in R&D, Richard was involved in the successful development and launch of two drugs in the competitive COPD and asthma markets (Breo® Ellipta® and Anoro® Ellipta®) and transitioned seven other projects from preclinical research into clinical development in therpeutic areas ranging from respiratory disease to anti-infectives and urology.
Richard holds an MBA from the UC Berkeley Haas School of Business and a B.Sc. (Hons) in Chemistry from the University of Manchester, UK.